Can enxidipine turn negative after taking it?

Enasidenib is a treatment option for people with a specific type of acute myeloid leukemia (AML) called IDH. 2(isocitrate dehydrogenase2) mutations in patients with newly diagnosed, refractory or relapsed AML. It is a targeted inhibitor that helps control the development of leukemia by inhibiting the activity of IDH2 mutant enzyme.

Although ensidipine can control the progression of AML to a certain extent, it is not a drug that can directly cause AML patients to become negative. Conversion from leukemia usually refers to a state of complete remission when leukemia cells are no longer detectable in the patient's bone marrow. However, achieving complete remission requires the combined effect of comprehensive treatment strategies, including chemotherapy, targeted therapy, hematopoietic stem cell transplantation, and others.

Ensidipine is commonly used to control the progression ofAML, slow down the progression of the disease, and prolong the survival time of patients. It inhibits the activity of IDH2 mutant enzyme and reduces the level of abnormal metabolite 2-hydroxyvalerate (2-HG), helping to restore normal cell differentiation and proliferation. This process helps reduce the number of AML cells, but it does not guarantee that all leukemia cells will be completely eliminated and the patient will become negative.

Achieving complete remission often takes time and may not be achieved by all patients. Some patients may require further treatments, such as chemotherapy, stem cell transplantation, etc., to help achieve complete remission. Therefore, the goals during ensidipine treatment are usually to control the progression of AML, reduce symptoms, and prolong patient survival, rather than directly causing leukemia to become negative.

In summary, ensidipine is useful for patients with specific types ofAMLIt is a beneficial treatment option for patients, which can help control the progression of the disease, slow down the deterioration of the disease, and extend the patient's survival time. However, it is not a drug that can directly cause leukemia patients to become leukemic, and achieving complete remission often requires the combined effects of a combination of treatment strategies.